文献速递其他结缔组织病

皮下注射托珠单抗治疗多关节型或全身型幼年特发性关节炎临床试验中的长期疗效与安全性

Long-term efficacy and safety of subcutaneous tocilizumab in clinical trials of polyarticular or systemic juvenile idiopathic arthritis.
PubMed 文献 · Rheumatology (Oxford) · 2024-01-01

本文报告两项52周开放标签1b期核心试验的长期扩展研究,评估皮下注射托珠单抗治疗多关节型或全身型幼年特发性关节炎的药代动力学、药效学、疗效(随访至3年)和安全性(随访至5年)。44例多关节型及38例全身型患者进入扩展研究,托珠单抗谷浓度维持在预期临床获益范围,药效学参数维持核心试验水平,长期安全性与已知安全性特征一致。

要点

  • 多关节型患者托珠单抗谷浓度均值约10 μg/ml,全身型约75 μg/ml,3年内维持稳定。
  • 扩展研究中多关节型6例(13.6%)报告严重不良事件,其中5例为严重感染。
  • 扩展研究中全身型5例(13.2%)报告严重不良事件,其中1例为严重感染。

核心结论

  • 多关节型或全身型幼年特发性关节炎患者接受皮下注射托珠单抗治疗可获得长期疾病控制,长期安全性与已知托珠单抗安全性特征一致。

研究设计与样本

  • 两项开放标签、52周1b期核心试验的长期扩展研究,纳入经研究者评估有充分应答的多关节型或全身型幼年特发性关节炎患者,继续按体重给药方案接受皮下注射托珠单抗治疗直至商业可及或最长5年。
  • 扩展研究中药代动力学、药效学和疗效评估最长3年,安全性评估最长5年。

主要发现

  • 44例多关节型患者和38例全身型患者进入长期扩展研究。
  • 托珠单抗谷浓度维持在预期提供临床获益的范围内,3年内均值多关节型约10 μg/ml、全身型约75 μg/ml。
  • 药效学参数(白细胞介素-6、可溶性白细胞介素-6受体、红细胞沉降率、C反应蛋白)在整个扩展研究中维持在核心试验达到的水平。
  • 按美国风湿病学会暂行标准判定的非活动性疾病:多关节型体重<30 kg组为90%(17/19),≥30 kg组为53%(8/15);全身型体重<30 kg组为91%(10/11),≥30 kg组为92%(12/13)。
  • 扩展研究中严重不良事件:多关节型6例(13.6%,其中5例严重感染),全身型5例(13.2%,其中1例严重感染)。

关键数值与推荐

  • 非活动性疾病按美国风湿病学会暂行标准判定。
  • 多关节型体重<30 kg组非活动性疾病90%(17/19),≥30 kg组53%(8/15)。
  • 全身型体重<30 kg组非活动性疾病91%(10/11),≥30 kg组92%(12/13)。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: To investigate the safety and efficacy of subcutaneous tocilizumab (SC-TCZ) treatment in a long-term extension (LTE) of clinical trials in polyarticular or systemic juvenile idiopathic arthritis (pJIA or sJIA). METHODS: Patients with pJIA or sJIA from two open-label, 52-week phase 1b core trials of SC-TCZ who had adequate response per investigator assessment entered the LTE and continued SC-TCZ treatment according to body weight-based dosing regimens until commercial availability or up to 5 years. Pharmacokinetics, pharmacodynamics, and efficacy were assessed for up to 3 years, and safety for up to 5 years in the LTE. RESULTS: Forty-four patients with pJIA and 38 patients with sJIA entered the LTE. Tocilizumab trough concentrations were maintained within the range expected to provide clinical benefit (mean values: pJIA, ∼10 μg/ml; sJIA, ∼75 μg/ml over 3 years). Pharmacodynamic parameters (interleukin-6, soluble interleukin-6 receptor, erythrocyte sedimentation rate, C-reactive protein) were maintained throughout the LTE at levels achieved in the core trials. Inactive disease per American College of Rheumatology provisional criteria was reported for 90% (17/19) and 53% (8/15) of patients with pJIA and 91% (10/11) and 92% (12/13) of patients with sJIA in the <30 and ≥30 kg body weight groups, respectively. Serious adverse events in the LTE were reported in six patients with pJIA (13.6%; five serious infections) and five patients with sJIA (13.2%; one serious infection). CONCLUSION: Patients with pJIA or sJIA experienced long-term disease control with SC-TCZ treatment. Long-term safety was consistent with the known tocilizumab safety profile. CLINICAL TRIAL REGISTRATION: clinicaltrials.gov, NCT02165345.

来源:Rheumatology (Oxford),查看原文。版权归原作者所有。

引用

  1. Brunner HI, Ruperto N, Ramanan AV, et al. Long-term efficacy and safety of subcutaneous tocilizumab in clinical trials of polyarticular or systemic juvenile idiopathic arthritis. Rheumatology (Oxford). 2024. PMID: 38552315. doi:10.1093/rheumatology/keae180

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。